ES2246915T3 - Composiciones para el tratamiento de anormalidades en filtraciones glomoleculares, de persistencia de canal arterial y de osteoporosis. - Google Patents

Composiciones para el tratamiento de anormalidades en filtraciones glomoleculares, de persistencia de canal arterial y de osteoporosis.

Info

Publication number
ES2246915T3
ES2246915T3 ES00984691T ES00984691T ES2246915T3 ES 2246915 T3 ES2246915 T3 ES 2246915T3 ES 00984691 T ES00984691 T ES 00984691T ES 00984691 T ES00984691 T ES 00984691T ES 2246915 T3 ES2246915 T3 ES 2246915T3
Authority
ES
Spain
Prior art keywords
group
peptide
leu
baselineskip
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00984691T
Other languages
English (en)
Spanish (es)
Inventor
Krishna G. Peri
Sylvain Chemtob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire Saint Justine
Original Assignee
Centre Hospitalier Universitaire Saint Justine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire Saint Justine filed Critical Centre Hospitalier Universitaire Saint Justine
Application granted granted Critical
Publication of ES2246915T3 publication Critical patent/ES2246915T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pipe Accessories (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Joints With Sleeves (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Water Treatment By Sorption (AREA)
ES00984691T 1999-12-06 2000-12-06 Composiciones para el tratamiento de anormalidades en filtraciones glomoleculares, de persistencia de canal arterial y de osteoporosis. Expired - Lifetime ES2246915T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45548399A 1999-12-06 1999-12-06
US455483 1999-12-06

Publications (1)

Publication Number Publication Date
ES2246915T3 true ES2246915T3 (es) 2006-03-01

Family

ID=23808998

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00984691T Expired - Lifetime ES2246915T3 (es) 1999-12-06 2000-12-06 Composiciones para el tratamiento de anormalidades en filtraciones glomoleculares, de persistencia de canal arterial y de osteoporosis.

Country Status (12)

Country Link
US (1) US7442763B2 (https=)
EP (1) EP1244693B1 (https=)
JP (1) JP2003516417A (https=)
AT (1) ATE298346T1 (https=)
AU (1) AU784630B2 (https=)
CA (1) CA2396739A1 (https=)
DE (1) DE60020997T2 (https=)
ES (1) ES2246915T3 (https=)
MX (1) MXPA02005626A (https=)
NZ (1) NZ520762A (https=)
WO (1) WO2001042281A1 (https=)
ZA (1) ZA200205795B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
ATE298346T1 (de) 1999-12-06 2005-07-15 Chu Sainte Justine Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis
EP1467738A1 (en) * 2001-10-08 2004-10-20 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
US20050059742A1 (en) * 2001-10-31 2005-03-17 Jabbour Henry Nicolas Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia
US7414029B2 (en) 2002-05-23 2008-08-19 Theratechnologies, Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
JP2006506327A (ja) * 2002-05-23 2006-02-23 セラテクノロジーズ インコーポレイティド プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP2846793A1 (en) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
US5508384A (en) * 1992-09-10 1996-04-16 New York University Polypeptide derived from a popamine receptor, and compositions and methods thereof
CN1118572A (zh) * 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
US5869281A (en) 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
JPH09504174A (ja) * 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
AU706443B2 (en) * 1994-04-22 1999-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Melanoma antigens
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
WO1996006856A1 (en) * 1994-08-31 1996-03-07 Robert Webber Dopamine receptor peptides and anti-peptide antibodies
EP2301562B1 (en) * 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
NZ302524A (en) 1995-01-25 1999-05-28 Cor Therapeutics Inc Dna encoding the c140 receptor, agonists and antagonists therefor and use in assays to detect vascular pressure abnormalities
US5877155A (en) * 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US6117839A (en) * 1995-06-07 2000-09-12 Gensci Regeneration Sciences, Inc. Bone stimulating factor
DE69733352T2 (de) * 1996-03-21 2006-04-27 Epimmune, Inc., San Diego Hla-a2.1 bindende peptide und deren verwendung
WO1998010651A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5955575A (en) * 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
AUPP320998A0 (en) * 1998-04-27 1998-05-21 Walter And Eliza Hall Institute Of Medical Research, The Tyrosine phosphatase IA-2 T-cell epitopes
US6984719B1 (en) * 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
ATE298346T1 (de) 1999-12-06 2005-07-15 Chu Sainte Justine Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis

Also Published As

Publication number Publication date
DE60020997T2 (de) 2006-05-24
AU2134001A (en) 2001-06-18
NZ520762A (en) 2005-02-25
AU784630B2 (en) 2006-05-18
ATE298346T1 (de) 2005-07-15
WO2001042281A1 (en) 2001-06-14
US20030017988A1 (en) 2003-01-23
DE60020997D1 (de) 2005-07-28
EP1244693B1 (en) 2005-06-22
JP2003516417A (ja) 2003-05-13
US7442763B2 (en) 2008-10-28
MXPA02005626A (es) 2004-09-10
CA2396739A1 (en) 2001-06-14
EP1244693A1 (en) 2002-10-02
ZA200205795B (en) 2007-01-31

Similar Documents

Publication Publication Date Title
ES2273849T3 (es) Composiciones farmaceuticas que comprenden compuestos ciclicos peptidometicos con giro beta.
JP6203215B2 (ja) プロミニン−１ペプチド断片およびその使用
ES2361621T7 (es) Peptidos de lactoferrina utiles como peptidos de penetracion celular.
ES2446292T3 (es) Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
ES2268854T3 (es) Inhibidores de la vascularizacion.
US12162915B2 (en) Cell penetrating peptides that inhibit IRF5 nuclear localization
ES2246915T3 (es) Composiciones para el tratamiento de anormalidades en filtraciones glomoleculares, de persistencia de canal arterial y de osteoporosis.
JP2014510758A (ja) ほ乳類において脂肪細胞を標的とするための方法および組成物
US20150093383A1 (en) Use of immunesuppressant receptor
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
HUE026131T2 (en) Beta-arresin effector and preparations and methods for their use
US20040023853A1 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
JP2007506713A (ja) 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用
ES2369470T3 (es) Antagonistas de un receptor acoplado a la proteina g.
JP2003516417A5 (https=)
JP6143270B2 (ja) マイオスタチン阻害ペプチド
WO2006041205A1 (ja) 血管形成促進剤
JP2015506960A (ja) β−アレスチンエフェクターおよび組成物ならびにそれらの使用方法
US7414029B2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
US11541101B1 (en) LEMD3 antagonizes TGF-beta-driven Smad2/3 transcription in a stiffness-dependent fashion in both the nucleus and cytosol
US7976837B2 (en) Method of preventing and treating brain infarction
WO2020000063A1 (en) Rheumatoid arthritis treatment